These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28862013)

  • 21. Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels.
    Mithoowani S; Moffat KA; Gupta A; Carlino SA; Crowther MA
    Thromb Res; 2022 Jul; 215():1-4. PubMed ID: 35580465
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.
    Ikeda K; Tachibana H
    J Arrhythm; 2016 Feb; 32(1):42-50. PubMed ID: 26949430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
    Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.
    Dreucean D; Nguyen SN; Donahue KR; Salazar E; Ruegger MC
    J Thromb Thrombolysis; 2021 Jul; 52(1):161-169. PubMed ID: 33099722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
    Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.
    Ofek F; Bar Chaim S; Kronenfeld N; Ziv-Baran T; Berkovitch M
    Clin Ther; 2017 May; 39(5):1003-1010. PubMed ID: 28476405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity].
    Delassasseigne C; Leroux C; Renou P; Girard D; Lafargue A; Morel S; Belotti PT; Weinmann L
    Ann Biol Clin (Paris); 2023 Jul; 81(3):269-279. PubMed ID: 37329142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients' Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips.
    Harenberg J; Hetjens S; Weiss C
    Clin Appl Thromb Hemost; 2022; 28():10760296221083667. PubMed ID: 35275493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels.
    Sabor L; Raphaël M; Dogné JM; Mullier F; Douxfils J
    Thromb Res; 2017 Aug; 156():36-38. PubMed ID: 28582639
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
    Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
    Platton S; Hunt C
    Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
    Smith AR; Dager WE; Gulseth MP
    Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.
    Wada S; Toyoda K; Sato S; Matsuki T; Okata T; Kumamoto M; Tagawa N; Inoue M; Okamoto A; Ihara M; Kitazono T; Miyata T; Koga M
    Circ J; 2018 Oct; 82(11):2872-2879. PubMed ID: 30210082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery.
    Kok T; de Boer H; Witteman B; Hovens M; van Luin M; Monajemi H
    Obes Surg; 2022 Mar; 32(3):607-614. PubMed ID: 34822108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
    Seredavkina NV; Reshetnyak TM; Satybaldyeva MA; Kashnikova LN; Temnikova TA; Nasonov EL
    Ter Arkh; 2019 May; 91(5):19-25. PubMed ID: 32598672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.